Clinical trials: Leukemia, Myeloid
Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor
Busulfan in Treating Children and Adolescents With Refractory CNS Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the safety of delivering intrathecal busulfan in children and adolescents who…
- Conditions
- Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Leukemia, Lymphoma
- Trial name
- NCT00006246
- Testing
- busulfan
- Where
- 8 sites in United States
- Volunteers
- 28 people
- Sponsor
- Pediatric Brain Tumor Consortium
Advanced Solid Tumors, Cancer
A Study of the Safety and Tolerability of ABBV-621 in Participants With Previously-Treated Solid Tumors and Hematologic Malignancies
This is an open-label, Phase I, dose-escalation study to determine the maximum tolerated dose (MTD) and/or recommended phase two dose (RPTD), and evaluate the safety, efficacy, and pharmacokinetic (PK) profile of ABBV-621 for…
- Conditions
- Advanced Solid Tumors, Cancer, Hematologic Malignancies
- Trial name
- NCT03082209
- Testing
- ABBV-621, Venetoclax, Bevacizumab
- Where
- 19 sites in United States, Japan and 2 more
- Volunteers
- 153 people
- Sponsor
- AbbVie
CML (Chronic Myelogenous Leukemia), Chronic Phase CML
ELVN-001 for the Treatment of Chronic Myeloid Leukemia With and Without T315I Mutation in Japanese Participants
The purpose of this study is to evaluate the safety, tolerability and determine the recommended dose for further clinical evaluation of ELVN-001 in Japanese patients with chronic phase chronic myeloid leukemia with and without…
- Trial name
- CML (NCT06787144)
- Testing
- ELVN-001
- Where
- 4 sites in Japan
- Volunteers
- 21 people
- Sponsor
- Enliven Therapeutics
Myelodysplastic Syndromes, Leukemia, Myeloid, Acute
Prophylactic DLI for the Prevention of Relapse Post HSCT in Patients With High Risk Myeloid Malignancy
The trial will be conducted as a multicentre open label, randomised prospective phase II clinical trial in patients with high risk myeloid malignancies.
- Trial name
- PRO-DLI (NCT02856464)
- Testing
- DLI will be administered to all patients at Month 4 (+/- 20 days) after stem cell transplant regardless of peripheral blood CD3 chimerism (including if they have full donor chimerism), DLI will be administered from Month 6 (+/- 20 days) after stem cell transplant according to institutional practice
- Where
- United Kingdom
- Volunteers
- 124 people
- Sponsor
- King's College Hospital NHS Trust
Acute Myeloid Leukemia
Ph I Safety and Efficacy of ODSH in Patients Receiving Induction or Consolidation Therapy for Acute Myeloid Leukemia
This is an open-label pilot study evaluating the safety and preliminary evidence of a therapeutic effect of ODSH (2-0, 3-0 desulfated heparin) in conjunction with standard induction and consolidation therapy for acute myeloid…
- Trial name
- NCT01843634
- Testing
- ODSH
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Jazz Pharmaceuticals
Refractory Leukemia
Chemotherapy CLAGE-Ven Sequential With Reduced Intensity Conditioning for Refractory Acute Myelodi Leukemia
The investigators developed a protocol combining chemotherapy of cladribine, cytarabine and etoposide (CLAGE) as debulking treatment sequential with reduced intensity conditioning regimen Flu-Bu to treat patients with refractory…
- Trial name
- NCT05870995
- Testing
- CALGE-VEN- RIC-conditioning
- Where
- 3 sites in China
- Volunteers
- 100 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Chronic Phase Chronic Myeloid Leukemia
A Study Comparing Ponatinib and Nilotinib in Participants With Chronic Myeloid Leukemia
The purpose of this study is to compare the efficacy and safety of 2 starting doses of ponatinib compared to nilotinib in participants with imatinib-resistant chronic myeloid leukemia (CML) in chronic phase (CP).
- Trial name
- OPTIC-2L (NCT02627677)
- Testing
- Ponatinib 30 mg QD, Ponatinib 15 mg QD, Nilotinib 400 mg BID
- Where
- Belgium
- Volunteers
- 44 people
- Sponsor
- Ariad Pharmaceuticals
Leukemia
"AIDA" Protocol (LAP 0493)
The main purposes of the AIDA protocol are to test the role of intermittent maintenance therapy with ATRA, standard maintenance chemotherapy with methotrexate and 6-mercaptopurine of both in PCR negative patients at the end of…
- Trial name
- NCT01064557
- Testing
- all-trans retinoic acid (ATRA)
- Where
- 80 sites in Belgium, Germany and 3 more
- Volunteers
- 1,068 people
- Sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia in Remission
Irradiated Donor Cells Following Stem Cell Transplant in Controlling Cancer in Patients With Hematologic Malignancies
This pilot clinical trial studies the side effects of irradiated donor cells following stem cell transplant in controlling cancer in patients with hematologic malignancies.
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia in Remission, Hematopoietic Cell Transplantation Recipient, JAK2 Gene Mutation
- Trial name
- NCT03272633
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Irradiated Allogeneic Cells
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Rutgers, The State University of New Jersey
Chronic Myeloid Leukemia in Chronic Phase
The Efficacy and Safety of Switching to Flumatinib Versus Dasatinib After Imatinib-related Low-grade Adverse Events in CML-CP Patients
The purpose of this study is to explore the efficacy and safety of switching to flumatinib versus dasatinib after imatinib-related low-grade adverse events in patients with chronic myeloid leukemia in chronic phase (CML-CP) in…
- Trial name
- NCT04933526
- Testing
- Flumatinib, Dasatinib
- Where
- China
- Volunteers
- 118 people
- Sponsor
- Shenzhen Second People's Hospital
Acute Myeloid Leukemia
Daunorubicin and Cytarabine With or Without Uproleselan in Treating Older Adult Patients With Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy
This phase II/III trial studies how well daunorubicin and cytarabine with or without uproleselan works in treating older adult patients with acute myeloid leukemia receiving intensive induction chemotherapy.
- Trial name
- NCT03701308
- Testing
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy
- Where
- 188 sites in United States
- Volunteers
- 267 people
- Sponsor
- National Cancer Institute (NCI)
Relapsed/Refractory Acute Myeloid Leukemia
Evaluate the Safety, Tolerability, Pharmacokinetic Profile, Efficacy of Bl-M11D1
The objective of this study to evaluate the safety, tolerability, pharmacokinetic profile, and preliminary efficacy of BL-M11D1 in patients with relapsed/refractory acute myeloid leukemia.
- Trial name
- NCT06714591
- Testing
- BL-M11D1
- Where
- 18 sites in United States
- Volunteers
- 52 people
- Sponsor
- SystImmune Inc.
Acute Myeloid Leukemia, Relapse/Recurrence
Bugitinib Combined With Venetoclax and Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia
This is a prospective, single-arm, exploratory study evaluating the combination of Bugitinib, Venetoclax, and Cytarabine in adult patients with relapsed or refractory acute myeloid leukemia (AML), excluding M3 subtype.
- Trial name
- NCT07563179
- Testing
- Bugitinib
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Shenzhen University General Hospital
AML (Acute Myelogenous Leukemia), MDS (Myelodysplastic Syndrome)
Forecasting Relapse Outcomes With AlloHeme-based Risk Detection in Post-Allo-HCT AML/MDS Patients (FORWARD)
AlloHeme is a blood-based monitoring test developed by the CareDx laboratory that utilizes NGS technology coupled with a proprietary algorithm to predict the likelihood of a relapse in post-allo-HCT AML/MDS patients.
- Conditions
- AML (Acute Myelogenous Leukemia), MDS (Myelodysplastic Syndrome), CMML
- Trial name
- FORWARD (NCT07607327)
- Testing
- AlloHeme
- Where
- 3 sites in United States
- Volunteers
- 400 people
- Sponsor
- CareDx
Acute Myeloid Leukemia
Targeted, Dose-Escalation Busulfan-Etoposide as Prep Regimen
Busulfan and etoposide have been used as preparative therapy for autoSCT (stem cell transplant) in adults with acute myeloid leukemia (AML) at UCSF for the past 10 years.
- Trial name
- Busulfan (NCT01048827)
- Testing
- Busulfan
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of California, San Francisco
Leukemia
4'-Thio-araC (Thiarabine) in Advanced Hematologic Malignancies
The goal of this clinical research study is to find the highest tolerable dose of 4'-thio-araC (thiarabine) that can be given to patients with advanced blood cancer.
- Trial name
- NCT01139151
- Testing
- 3 Day Thiarabine, 5 Day Thiarabine
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- M.D. Anderson Cancer Center
Myelodysplastic Syndrome, Acute Myeloid Leukemia
Study of 72-Hour Infusion of ON 01910.Na in Patients With MDS or AML
The primary objective of this study is to evaluate the efficacy and safety of ON 01910.Na Concentrate when it is administered as an intravenous continuous infusion (IVCI) over 72 hours once every 2 weeks in a broad population of…
- Trial name
- NCT00854945
- Testing
- ON 01910.Na
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Traws Pharma, Inc.
AML, Acute Myelogenous Leukemia
Diagnosis and Treatment of Periodontal Disease in Patients With AML
This is a phase 2 randomized controlled trial of pre-chemotherapy periodontal deep cleaning in Acute Myelogenous Leukemia (AML) patients with asymptomatic periodontitis.
- Trial name
- NCT04530695
- Testing
- Scaling and Root Planing
- Sponsor
- Masonic Cancer Center, University of Minnesota
Hematopoietic System--Cancer
Improved Post-Transplant Cyclophosphamide Regimens for Pediatric Patients With Refractory AML
No more datas about post-transplant cyclophosphamide (PT/Cy) used in pediatric refractory acute myeloid leukemia (R-AML）patients.
- Trial name
- NCT03654703
- Testing
- Cyclophosphamide
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Capital Research Institute of Pediatrics
Hematological Malignancy
KATALYST-HEME-01: Study of the KAT6 Inhibitor MEN2312 in Heme Malignancies
This study will evaluate safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and activity of MEN2312 in participants with hematological malignancies.
- Trial name
- NCT07873827
- Testing
- MEN2312
- Volunteers
- 115 people
- Sponsor
- Stemline Therapeutics, Inc.